rpl-10a Antibody

What is RPL10A and why is it important in research?

RPL10A (also known as uL1, NEDD6, or CSA-19) is a component of the 60S ribosomal subunit involved in protein synthesis. It has emerged as a critical factor in developmental biology, particularly in mesoderm formation. RPL10A functions beyond basic protein synthesis, regulating translation of specific mRNAs including Wnt pathway components, which are crucial for embryonic development . An RPL10A loss-of-function allele in mice causes striking mesodermal phenotypes and posterior trunk truncations, indicating its essential role in development . By studying RPL10A, researchers can gain insights into ribosome heterogeneity and specialized translation of developmental signaling networks.

What applications are RPL10A antibodies validated for?

RPL10A antibodies have been validated for multiple applications across various experimental contexts:

Researchers should note that optimal dilutions may be sample-dependent and should be determined empirically for each experimental system .

How do I select the appropriate RPL10A antibody for my research?

Selection depends on several factors:

• Host species: Both rabbit polyclonal (higher sensitivity, broader epitope recognition) and mouse monoclonal (higher specificity, better reproducibility) options are available .

• Reactivity: Available antibodies show confirmed reactivity with human, mouse, and rat samples, with potential cross-reactivity in other species based on sequence homology .

• Application: Consider antibodies specifically validated for your application of interest. For example, 16681-1-AP has been validated for WB, IF/ICC, IP, CoIP, ELISA, and PLA applications .

• Immunogen type: Options include full-length recombinant proteins (e.g., OTI4B2 clone) or specific peptide sequences (e.g., ab226381 targeting amino acids 50-100) .

Always review validation data from manufacturers and published literature before selection.

What molecular weight should I expect for RPL10A in Western blots?

The calculated molecular weight of RPL10A is 24.7-25 kDa , and this corresponds to the observed band in Western blots. When performing Western blotting, a band at approximately 25 kDa indicates successful detection of RPL10A. Variations in observed molecular weight may occur due to post-translational modifications or sample preparation conditions. Multiple commercial antibodies consistently detect RPL10A at this expected size across various cell lines including HeLa, HEK-293T, and Jurkat cells .

What are the optimal lysis conditions for RPL10A detection in Western blotting?

For efficient RPL10A extraction and detection:

• Buffer composition: NETN lysis buffer has been successfully used for RPL10A Western blotting . Additionally, standard RIPA buffer supplemented with protease inhibitors is suitable for most applications.

• Sample types: RPL10A antibodies have been validated in various sample types including:

  • Cell lines: HeLa, HepG2, HEK-293T, Jurkat, SKOV3, U-937

  • Tissues: Human brain and liver, mouse spleen, rat spleen and uterus

• Protocol considerations:

  • Add fresh protease inhibitors to lysis buffer

  • Maintain samples at 4°C during processing

  • For complete extraction of nuclear-associated ribosomes, include sonication or nuclease treatment steps

  • Use sample-specific optimized protocols, as provided by some manufacturers

How should I design immunofluorescence experiments to detect RPL10A?

For optimal immunofluorescence detection:

• Fixation method: Methanol fixation at room temperature for 5 minutes has been successful for RPL10A detection . Alternatively, 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100 can be used.

• Blocking conditions: Use PBS containing 0.1% Triton X-100, 1% BSA, and 22.52 mg/ml glycine for 30 minutes to reduce background .

• Antibody dilution: Use RPL10A antibodies at 1:50-1:200 dilution for immunofluorescence applications . For co-localization studies with other ribosomal markers, consider using mouse anti-His tag antibodies for tagged RPL10A constructs .

• Controls: Include negative controls (secondary antibody only) and positive controls (known RPL10A-expressing cells like HepG2) .

• Washing steps: Perform thorough washing with PBS (at least 3 washes of 5 minutes each) after both primary and secondary antibody incubations.

What are the recommended procedures for immunoprecipitation of RPL10A?

For successful RPL10A immunoprecipitation:

• Antibody amount: Use 0.5-4.0 μg of RPL10A antibody for 1.0-3.0 mg of total protein lysate .

• Lysis conditions: Use non-denaturing lysis buffers that preserve protein-protein interactions, especially important for studying RPL10A interactions with other ribosomal components or mRNAs.

• Protocol steps:

  • Pre-clear lysate with protein A/G beads

  • Incubate cleared lysate with RPL10A antibody (4-16 hours at 4°C)

  • Add fresh protein A/G beads and incubate (1-4 hours at 4°C)

  • Wash extensively to remove non-specific binding

  • Elute bound proteins for downstream analysis

• Validation: RPL10A antibodies have been successfully used for IP in HeLa cells , making these cells an appropriate positive control.

• Troubleshooting: If IP efficiency is low, consider crosslinking the antibody to beads to prevent antibody co-elution with the target protein.

How can RPL10A antibodies be used to study ribosome heterogeneity?

Ribosome heterogeneity refers to variations in ribosome composition that may regulate gene expression through specialized translation. RPL10A antibodies can be instrumental in this research:

• Ribosome profiling: Using RPL10A antibodies for translating ribosome affinity purification (TRAP) can isolate RPL10A-containing ribosomes for subsequent RNA-seq analysis to identify mRNAs preferentially translated by these ribosomes .

• Comparative analysis: By comparing the translation efficiency of specific mRNAs in wild-type vs. RPL10A-deficient cells, researchers can identify transcripts dependent on RPL10A for efficient translation, such as Wnt pathway components .

• Developmental timing studies: Since ribosome composition changes during stem cell differentiation, RPL10A antibodies can track changes in ribosome composition during development through quantitative immunofluorescence or Western blotting .

• Co-immunoprecipitation: RPL10A antibodies can be used to identify proteins that interact with RPL10A-containing ribosomes, potentially revealing regulatory factors that mediate specialized translation.

• Embryonic development research: Given RPL10A's role in mesoderm formation, tissue-specific immunostaining using these antibodies can map RPL10A expression patterns during critical developmental stages .

What considerations are important when using RPL10A antibodies in CRISPR-edited models?

When working with CRISPR-edited models affecting RPL10A:

• Epitope preservation: Consider the location of CRISPR-induced mutations relative to antibody epitopes. For example, if using an antibody targeting amino acids 50-100 (like ab226381) , mutations in this region may affect antibody binding even if the protein is expressed.

• N-terminal modifications: Research has used CRISPR/Cas9 with gRNAs targeting the 5' end of the RPL10A coding sequence to mutate the solvent-exposed N-terminus . When working with such models, select antibodies targeting other regions of the protein.

• Validation approaches: For CRISPR knock-in models with tags (e.g., His-tag), consider dual validation using both RPL10A antibodies and tag-specific antibodies .

• Functional validation: Since RPL10A loss-of-function in mice causes developmental phenotypes including posterior trunk truncations , phenotypic analysis should complement antibody-based validation of CRISPR editing.

• Control selection: Include appropriate controls such as wild-type samples and, if possible, samples with known RPL10A variants to confirm antibody specificity in the context of your genetic modifications.

How can I use RPL10A antibodies to investigate the role of specialized ribosomes in development?

Recent research has revealed that RPL10A plays a specific role in mesoderm development through selective translation of key developmental mRNAs . To investigate this phenomenon:

• Tissue-specific analysis: Use RPL10A antibodies for immunohistochemistry on embryonic sections to map expression patterns during development. Focus on mesoderm derivatives where RPL10A function appears critical .

• Differential ribosome purification: Combine RPL10A immunoprecipitation with sucrose gradient fractionation to isolate specific ribosome subpopulations for proteomic and transcriptomic analysis.

• Translational reporter assays: Design reporter constructs containing 5' and 3' UTRs of suspected RPL10A-dependent mRNAs (e.g., Wnt pathway components) and assess translation efficiency in the presence or absence of RPL10A.

• Stem cell differentiation models: Apply RPL10A antibodies to track changes in ribosome composition during directed differentiation of embryonic stem cells toward mesodermal lineages .

• Proximity ligation assays (PLA): Use RPL10A antibodies in PLA experiments to detect interactions with specific mRNAs or regulatory proteins in situ, providing spatial information about these interactions during development.

What are common issues when using RPL10A antibodies and how can I address them?

When working with RPL10A antibodies, researchers may encounter several challenges:

• Multiple bands in Western blot:

  • Potential cause: Degradation products, post-translational modifications, or non-specific binding

  • Solution: Optimize extraction conditions, use fresh protease inhibitors, try different blocking agents (5% milk vs. 5% BSA), adjust antibody concentration (1:1000-1:4000 for WB)

• High background in immunofluorescence:

  • Potential cause: Insufficient blocking, excessive antibody concentration, or non-specific binding

  • Solution: Increase blocking time, dilute antibody further (1:50-1:200 range) , include additional washing steps, or try a monoclonal alternative

• Weak signal in immunoprecipitation:

  • Potential cause: Insufficient antibody amount, inadequate incubation time, or inefficient cell lysis

  • Solution: Increase antibody amount (up to 4.0 μg per reaction) , extend incubation time, optimize lysis buffer composition

• Inconsistent results across experiments:

  • Potential cause: Antibody degradation or variability in experimental conditions

  • Solution: Aliquot antibodies to avoid freeze-thaw cycles, standardize protocols, include positive controls in each experiment

• Cross-reactivity with related proteins:

  • Potential cause: Antibody recognizing conserved ribosomal protein epitopes

  • Solution: Validate specificity using RPL10A knockdown/knockout samples, consider using monoclonal antibodies with higher specificity

How do I interpret differences in RPL10A expression across tissues or developmental stages?

Interpreting RPL10A expression patterns requires careful consideration:

How is RPL10A contributing to our understanding of specialized translation?

Recent research has revealed RPL10A's role beyond general protein synthesis:

• Selective mRNA translation: Loss of RPL10A affects translation of specific mRNAs, particularly those in the Wnt signaling pathway, demonstrating that ribosome composition can influence which mRNAs are preferentially translated .

• Developmental regulation: RPL10A levels change during stem cell differentiation, suggesting that ribosome composition is dynamically regulated during development .

• Signaling pathway integration: RPL10A regulates both canonical and non-canonical Wnt signaling during stem cell differentiation and embryonic development, indicating that specialized ribosomes can modulate core developmental signaling networks .

• Structural insights: As part of the large ribosomal subunit, RPL10A's position may allow interaction with specific mRNA features, potentially explaining its selective influence on certain transcripts .

These findings challenge the traditional view of ribosomes as passive translation machinery and suggest they actively participate in gene regulation through specialized composition.

What are emerging applications of RPL10A antibodies in disease research?

While primarily studied in developmental contexts, RPL10A antibodies have potential applications in disease research:

• Cancer biology: As protein synthesis is frequently dysregulated in cancer, investigating RPL10A expression and its selective translation of signaling molecules like Wnt pathway components may provide insights into cancer progression mechanisms.

• Developmental disorders: Given RPL10A's role in mesoderm formation, antibodies can help investigate developmental disorders associated with mesodermal defects by analyzing RPL10A expression patterns in patient-derived cells or tissues.

• Ribosome-related diseases: "Ribosomopathies" are conditions caused by ribosomal protein mutations or deficiencies. RPL10A antibodies can help characterize ribosome composition changes in these disorders.

• Stem cell therapies: As stem cell differentiation involves changes in ribosome composition including RPL10A , these antibodies can monitor differentiation status and help optimize protocols for regenerative medicine.

• Drug discovery: Compounds affecting RPL10A-dependent translation could represent novel therapeutic approaches for conditions involving aberrant Wnt signaling. RPL10A antibodies would be essential tools in such drug screening efforts.

What are the best practices for maintaining RPL10A antibody quality and experimental reproducibility?

To ensure optimal results when working with RPL10A antibodies: